LearnGlossaryMarketStocksSuperinvestorsSign in

CRIS

Curis, Inc.

Healthcare · $2M market cap

Verdict

We can't put a fair value on CRIS right now. It looks like a preferred share, note or other security rather than ordinary common stock. The figures we receive belong to the parent company, so they can't value this security.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-11.6% a year✗
Sales growth-1.6% a year✗
Free cash flow growth—?
Return on invested capital-55.5%✗

Follow CRIS

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds CRIS. Who we track

Lee Ainslie

Maverick Capital · as of Q2 2026

$6.2M

49,554 shares

About Curis, Inc.

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works